News › Industry News, News

Breaking Business News: Allergan Acquires Bonti

September 18, 2018

Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications.
Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic).
Read more at DermWire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Federal Bill Would Establish New Ownership and Management Requirements for Medical Practices
    • CBS News Investigation Raises Concerns About Unapproved Retatrutide Sales
    • FDA Approves Belotero Volume and Belotero Intense
    • Ad IntellX Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • SafeLink Consulting Inc. Launches SafeLink360, Bringing Risk & Compliance Management and Expert Support Together in One Platform
Advertisement